SCHEMBL2395569

SCHEMBL2395569

Clc1cc(Oc2cc[c]cc2)ccc1OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
NFKB1 P19838 2/20 0.48
NFKB2 Q00653 2/20 0.48
RELA Q04206 2/20 0.48
MRGPRX4 Q96LA9 8/20 0.46
MAOB P27338 1/20 0.41
HPGD P15428 4/20 0.41
PPARG P37231 1/20 0.41
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41
EGFR P00533 2/20 0.41
ERBB2 P04626 1/20 0.41
ACP1 P24666 1/20 0.40
PTPN12 Q05209 1/20 0.40
PTPN13 Q12923 1/20 0.40
SSU72 Q9NP77 1/20 0.40
MEN1 O00255 1/20 0.40
MITF O75030 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13047045 0.84 MRGPRX4 (0.52) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL3758682 0.84 MAOB (0.61) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL2397862 0.83 SCN9A (0.46) MRGPRX4MAOBPPARD
SCHEMBL2399539 0.83 MEN1 (0.40) NPC1RAB9ASMN1; SMN2MAOBMEN1
SCHEMBL17658995 0.82 ALOX5 (0.58) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL2705229 0.81 MRGPRX4 (0.65) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL2262271 0.80 LMNA (0.58) RAB9ASMN1; SMN2MAOBPPARGMAPT
SCHEMBL3245821 0.80 MAPT (0.42) RAB9ASMN1; SMN2PPARGPPARDPPARA
SCHEMBL27863231 0.78 POLB (0.50) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL2265075 0.78 MAOB (0.58) MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237528-A1 COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-09-29 US disclosed
US-20100144733-A1 Compounds, compositions and methods comprising heteroaromatic derivatives INSTITUTE FOR ONEWORLD HEALTH 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144733-A1 Compounds, compositions and methods comprising heteroaromatic derivatives CFTR, PKD1, PKD2 NPC1 233/4885RAB9A 2192/4885SMN1; SMN2 4546/4885
US-20110237528-A1 COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES CFTR, PKD1, PKD2 NPC1 510/4885RAB9A 2348/4885SMN1; SMN2 4721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.